Outcomes in Systemic Sclerosis-Associated Interstitial Lung Disease Based on Serological Profiles: Focus on Anti-Centromere and Anti-RNA Polymerase III Antibodies

By sjmartinez • April 16, 2025

Volkmann ER, Assassi S, Denton CP, Simonovska R, Sambevski S, Alves M, Bernstein EJ. Outcomes in Systemic Sclerosis-Associated Interstitial Lung Disease Based on Serological Profiles: Focus on Anti-Centromere and Anti-RNA Polymerase III Antibodies. J Rheumatol. 2025 Apr 15:jrheum.2024-1063. doi: 10.3899/jrheum.2024-1063. Epub ahead of print. PMID: 40233987.

Tags: Publications, Rheumatology

Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial

Abrisqueta P, Karimi YH, Morillo D, Cordoba R, Phillips T, De Vos S, Nijland M, Offner F, Andersson PO, Brody J, Cheah CY, Prieto PG,[...]

Neoadjuvant BO-112 and hypofractionated radiation therapy with or without nivolumab in soft tissue sarcoma: preclinical and phase 1 results

Deng J, Pal A, Testa S, Xu JW, Tran LM, Graham DS, Hargil A, Subramanian A, Campbell KM, Limsuwannarot S, Chumpitaz Lavalle Á, Chin SC,[...]

Peak Oxygen Uptake Prediction From Resting and Submaximal Variables of Cardiopulmonary Exercise Testing

Lee Y, Feng J, Rahrooh A, Bui AAT, Cooper CB, Hsu JJ. Peak Oxygen Uptake Prediction From Resting and Submaximal Variables of Cardiopulmonary Exercise Testing.[...]